(3-Chlor-salicylsaeure)-anilid | 51460-79-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-Chlor-salicylsaeure)-anilid
• 英文别名: 5-Chlorsalicylanilid；3-chloro-2-hydroxy-benzoic acid anilide；3-Chlor-2-hydroxy-benzoesaeure-anilid；Chlorosalicylanilide；3-Chlorosalicylanilide；3-chloro-2-hydroxy-N-phenylbenzamide
• CAS: 51460-79-8
• 化学式: C₁₃H₁₀ClNO₂
• 分子量: 247.681
• InChiKey: GOCQZGNVXYJCIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯胺 、 alkaline earth salt of/the/ methylsulfuric acid 在 乙醚 作用下， 生成 (3-Chlor-salicylsaeure)-anilid
  参考文献：
  名称：

  Anschuetz; Anspach, Justus Liebigs Annalen der Chemie, 1906, vol. 346, p. 314

  摘要：

  DOI：

文献信息

• Cosmetic composition
  申请人：UNILEVER PLC

  公开号：EP0489581A2

  公开（公告）日：1992-06-10

  Compositions containing an ester of nicotinic acid and a cosmetically acceptable surfactant are provided. These compositions, when applied topically to the human body produce a response such as a sensory or therapeutic response, for example a tingling or warming sensation or an increase in blood flow, which persists after the composition is rinsed from the body. The compositions are particularly suitable for application to the hair and/or scalp where they may encourage hair growth. Compositions for application to the hair and/or scalp preferably additionally comprise hair benefit agents such as hair growth promoters.

  提供含有烟酸酯和化妆品可接受的表面活性剂的组合物。这些组合物在局部涂抹到人体时会产生一种感官或治疗反应，例如刺痛或温热感觉，或者增加血液流动，这种反应在组合物被冲洗后仍然持续。这些组合物特别适用于涂抹到头发和/或头皮，可以促进头发生长。用于涂抹到头发和/或头皮的组合物最好还包括头发益处剂，如促进头发生长的剂。
• Impregnating waterproofing composition
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：EP0469624A1

  公开（公告）日：1992-02-05

  An impregnating waterproofing composition suitable for treating inorganic materials, which is excellent not only in antifungal and mildewproofing, but also in waterproofness and durability, comprises an known organoalkylalkoxysilane or its derivative[component(A)] and another organosilicon compound containing a quaternary ammonium halide groups and having a condensable alkoxy group [component(B)] as the main ingredients.

  一种适用于处理无机材料的浸渍防水组合物，不仅具有优异的防霉和防霉性能，还具有防水性和耐久性，其主要成分包括一种已知的有机烷基烷氧基硅烷或其衍生物[组分（A）]和另一种含有季铵卤化物基团并具有可缩合烷氧基的有机硅化合物[组分（B）]。
• Isotope enhanced ambroxol for long lasting autophagy induction
  申请人：STC.UNM

  公开号：US10583099B2

  公开（公告）日：2020-03-10

  The present invention is directed to 2H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drug resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy) are also disclosed. These compositions are useful against an autophagy mediated disease state and/or condition), especially an autophagy mediated disease state and/or condition which occurs in the lungs.

  本发明涉及2H同位素增强型氨溴索（"同位素增强型氨溴索"）及其在治疗自噬感染，特别是分枝杆菌和其他感染、疾病状态和/或肺部状况，如结核病，尤其包括耐药性和多重耐药性结核病中的应用。此外，还公开了包含同位素增强型氨溴索的药物组合物，该药物组合物可单独使用，也可与其他生物活性制剂（尤其是利福霉素抗生素）组合使用，包括其他自噬调节剂（具有促进或抑制自噬活性的制剂）。这些组合物可用于防治自噬介导的疾病状态和/或病症，尤其是发生在肺部的自噬介导的疾病状态和/或病症。
• TREATMENT OF AUTOPHAGY-RELATED DISORDERS
  申请人：DERETIC Vojo P.

  公开号：US20160136123A1

  公开（公告）日：2016-05-19

  The present invention relates to the use of neutral lipids, including triglycerides, diglycerides and monoglycerides which may be used to increase neutral lipids (lipid stores and/or lipid droplets) and neutral lipid stores in order to regulate (in particular, induce) autophagy and treat and/or prevent autophagy related disease states and/or conditions. In one embodiment, the invention relates to the use of neutral lipids and/or TRIM proteins which may be used to regulate (in particular, induce) autophagy, target autophagic substrates and treat and/or prevent autophagic disease states and/or conditions.
• ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION
  申请人：STC.UNM

  公开号：US20190269806A1

  公开（公告）日：2019-09-05

  The present invention is directed to 13 C and/or 2 H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drag resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy), thus being useful against, an autophagy mediated disease state and/or condition), especially an autophagy mediated disease state and/or condition which occurs in the lungs, for example, a Mycobacterium infection. Chronic Obstructive Pulmonary Disease (COPD), asthma, pulmonary fibrosis, cystic fibrosis, Sjogren's disease and lung cancer (small cell and non-small cell lung cancer, among other disease states and/or conditions, especially of the lung. Methods of treating autophagy disease states and/or conditions, especially including autophagy disease states or conditions which occur principally in the lungs of a patient represent a further embodiment of the present invention. An additional embodiment includes methods of synthesizing compounds according to the present invention as otherwise disclosed herein.